Melbourn promotes Derek Solomon

Moves from laboratory manager to operations director

Melbourn Scientific, a UK provider of analytical and formulation contract research services for the pharma and biotech industries, is broadening its management team with the promotion of laboratory manager Derek Solomon to the new role of operations director.

Solomon joined Melbourn Scientific in 2005 and has overseen the expansion of the services portfolio, which included the recent addition of clinical manufacture to its formulation development services.

You may also like

Research & Development

Intertek acquires Melbourn Scientific

Combines advanced capabilities for measuring device/drug interaction with OINDP drug characterisation expertise
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A finite resource: helium

Although helium may be the second most abundant element in the universe, here on earth this noble gas is rare and precious. In the pharmaceutical industry helium is used for cryogenic cooling of magnets used for MRI and in gas chromatography
Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development

New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research

Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development

Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery

The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development

GlaxoSmithKline and Oxford BioTherapeutics partner to advance antibody-based therapeutics for cancer

The collaboration leverages OBT's proprietary OGAP-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
Subscribe now